How the semaglutide titration works

Semaglutide is a GLP-1 receptor agonist given as a once-weekly subcutaneous injection. For weight loss, the target dose is 2.4 mg weekly. You do not start there. The body needs time to adapt to the medication, so prescribers use a 4-week step-up protocol that helps reduce nausea, fatigue, and gastrointestinal side effects.

The 5 dose steps in detail

Each step lasts roughly 4 weeks. If side effects are mild, you move up on schedule. If they are intolerable, your prescriber will typically hold you at the current dose for another 4 weeks before escalating.

  • Step 1, 0.25 mg (weeks 1 to 4): GI adjustment dose. Weight loss at this stage is usually modest, though some patients notice early appetite changes. Nausea is most common in the first week after each bump.
  • Step 2, 0.5 mg (weeks 5 to 8): First dose with a measurable appetite effect. Patients often report early weight loss of 2 to 4 pounds.
  • Step 3, 1.0 mg (weeks 9 to 12): Many patients notice clearer appetite reduction and smaller portion sizes at this dose. Reduced cravings are also commonly reported.
  • Step 4, 1.7 mg (weeks 13 to 16): Patients may experience increased fullness and continued appetite reduction. Many are losing noticeable weight by this stage, and the dose is generally well tolerated.
  • Step 5, 2.4 mg (week 17 onward): Full maintenance dose. Clinical trials have shown average weight loss in the 10 to 15 percent range by month 6, though individual results vary significantly.

What to do if you cannot tolerate a step

The safest move is always to talk to your prescriber. The common clinical response is to stay at the current dose for another 4 weeks, rather than skipping ahead or stopping the medication entirely. For some patients, 1.7 mg becomes the long-term maintenance dose because the full 2.4 mg causes significant gastrointestinal side effects.

Never self-escalate or self-taper. Dose adjustments should be directed by a licensed prescriber who can evaluate the side effect profile in context.

Frequently asked questions

How long does it take to reach the full 2.4 mg semaglutide dose?

The standard titration takes 16 weeks. Each step lasts 4 weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and then 2.4 mg starting at week 17. Some patients need longer at one or more steps if side effects are not well tolerated.

What is the starting dose of semaglutide for weight loss?

The starting dose is 0.25 mg once weekly for the first 4 weeks. This dose is primarily intended for medication adjustment and side-effect reduction. Some patients notice early appetite or weight changes, but the larger therapeutic effect is typically seen at higher doses.

Can you stay on a lower semaglutide dose long term?

Yes. Some patients stay at 1.7 mg or even 1.0 mg if they are losing weight well and tolerating side effects. Staying below the 2.4 mg maintenance dose should only be done under a prescriber's guidance.

What should I do if side effects are too strong at one dose step?

Talk to your prescriber. The common clinical response is to hold the current dose for an additional 4 weeks before escalating, rather than skipping ahead or stopping. Never self-adjust the dose without medical supervision.

Is the Ozempic dosage schedule the same as Wegovy?

Close but not identical. Ozempic is FDA-approved for type 2 diabetes and tops out at 2.0 mg weekly. Wegovy is FDA-approved for weight loss and tops out at 2.4 mg weekly. When Ozempic is used off-label for weight loss, many clinicians still follow the Wegovy titration path.

What dose of semaglutide is 20 units?

Dose conversions for compounded semaglutide vary depending on the pharmacy concentration and formulation. A "20 unit" measurement on an insulin syringe corresponds to different mg amounts depending on the vial. Always confirm dosing instructions directly with your prescriber or pharmacist before injecting.

Sources

  1. 1.Wegovy (semaglutide) injection 2.4 mg Prescribing Information. Novo Nordisk, 2024.
  2. 2.STEP 1 trial: Once-weekly semaglutide in adults with overweight or obesity. NEJM, 2021.
  3. 3.FDA label: NDA 215256 (Wegovy). Drug Approval Package.

This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer

Dosing watch

Dosing schedules change?

One short email when titration guidance, side-effect data, or maintenance-dose research updates.